Firsocostat

Firsocostat (CAS No.: 1434635-54-7) is a synthetic small-molecule allosteric inhibitor of acetyl-CoA carboxylase (ACC), also known as GS-0976, ND-630, and NDI-010976, for use in lipid metabolism and metabolic disease biology research in the context of biomedical research and drug development; by binding to the dimerization interface of ACC and blocking the formation of the catalytic dimer, it reduces intracellular malonyl-CoA production, thereby inhibiting de novo lipogenesis and promoting fatty acid oxidation, and shows highly potent inhibitory activity against human ACC1 and ACC2 at low nanomolar levels (reported IC50 values of 2.1 nM and 6.1 nM, respectively); in hepatocyte-derived models (such as HepG2), clear on-target cellular effects can be observed at nanomolar effective concentrations under both serum-containing and serum-free conditions, and it maintains broad selectivity against multiple classes of enzymes, receptors, transporters, and ion channels at micromolar levels; typical applications include use as a chemical probe for mechanistic analysis of ACC-dependent pathways, target validation, and high-content/phenotypic screening, as well as investigation of experimental questions such as lipid accumulation and energy metabolism in liver-related cells and rodent metabolic research models; the concentrations or doses used in experiments generally need to be optimized and defined according to the specific experimental design and research objectives; this product is for laboratory research use only and is not intended for human or veterinary use, diagnosis, or any form of ingestion.